Navigation Links
Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
Date:5/7/2009

of our existing product pipeline and will allow us to grow our sales organization to better position us for growth with our current and future products. We will also be in a good position to evaluate and execute on opportunities to acquire or in-license other high-quality respiratory drugs. This agreement provides us with the opportunity to work closely with Chiesi, one of Europe's most highly-respected and successful pharmaceutical companies, and achieves our stated goal of making a significant product acquisition in 2009 and increasing our penetration in the respiratory market."

"Our investment in Cornerstone demonstrates our confidence in their ability to continue growing their business in an efficient and strategic manner," said Alberto Chiesi, Chiesi's President & CEO. "Moreover, as the respiratory therapeutic space represents approximately 46 percent of our business, we are pleased to establish a relationship with a company with the good respiratory expertise that Cornerstone possesses. We believe this agreement has the potential to meaningfully increase our footprint in the U.S., the world's largest pharmaceutical market."

The closing of the transaction is subject to the approval of Cornerstone's stockholders, receipt of regulatory approvals and other customary closing conditions. The parties anticipate that the stockholders' meeting will be held in the third quarter of 2009. The board of directors of each company has approved the agreements. Houlihan Lokey served as financial advisor to Cornerstone, and Clifford Chance US LLP provided legal counsel to Cornerstone. Morgan, Lewis & Bockius LLP provided legal counsel to Chiesi.

Cornerstone will provide further details on this transaction during today's previously scheduled earnings conference call, which will begin at 8:30 AM ET. To participate in the live conference call, please dial 866-783-2137 (U.S. callers) or 857-350-1596 (international)
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
2. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
3. Cornerstone Therapeutics Announces New Board of Directors
4. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
5. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
6. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
7. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
8. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
9. Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and Infections
10. Prime Therapeutics Announces Departure of President and Chief Executive Officer Timothy Dickman
11. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired by ... in March, Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative medicine ... with demonstrated financial need. , “We are thrilled for this opportunity to offer ...
(Date:7/29/2015)... ... July 29, 2015 , ... Stealth ... a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, ... options, offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... from the Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys ... at their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global ...
(Date:7/29/2015)... ... ... The Woodlands and Spring Fit Body Boot Camps have implemented an engaging ... month. The new system will track each time a client uses social media to ... the boot camps will donate 20 cents to a selected charity. , Fit Body ...
(Date:7/29/2015)... ... July 29, 2015 , ... Indiana is known for basketball, the boyhood home ... Zerorez Indianapolis, which plans to expand across the state. , Ray Kennedy, owner of ... year in business and we should double our first year’s revenue. More importantly, ...
Breaking Medicine News(10 mins):Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3
... Joe Pesci (Goodfellas) , Dennis Haysbert ... Simmons (The Closer/Juno) , Kenny Lofton (MLB - ... , will be teeing it up on Monday, May 11th for Melanoma ... n, Smack was named TOP 10 in SoCal by Southland Golf Magazine in ...
... Nursing baby brings cardiovascular benefits decades later, study suggests, ... just good for baby, it may also boost mom,s ... , Women in their 60s who had breast-fed for ... 10 percent less likely to develop cardiovascular disease, and ...
... League, Human Life International, Pharmacists for Life ... Nation and Pro-Life Unity released the following ... Sebelius to Health and Human Services director.(Logo: ... groups represent hundreds of thousands of supporters ...
... recently announced the launch of "Frontiers of Retrovirology", an ... researchers to review current progress and to chart future ... date, 25 million have died from AIDS. In 2007 ... and 2 million new AIDS deaths were registered. A ...
... announced earlier today that Emetrol (R) , its liquid ... Based on trailing 52 weeks sales (ending 1/14/09) ... all others including private label. The most recent IRI ... 24% over last year reflecting the fact that it is ...
... N.J., April 21 BullMarket.com ( http://www.bullmarket.com ... and income-generating stocks, has provided subscribers with coverage of medical ... ISRG ), Gen-Probe (Nasdaq: GPRO ), St. Jude ... COV ), and Synovis (Nasdaq: SYNO ), among ...
Cached Medicine News:Health News:Top Celebs Tee it for Melanoma at 6th annual Hack n' Smack (Top 10 in Southland Golf Mag) 2Health News:Breast-feeding a Boon to Mom's Heart 2Health News:Breast-feeding a Boon to Mom's Heart 3Health News:Groups: Sebelius Unfit For Office in Wake of New Revelations 2Health News:WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category 2Health News:BullMarket.com Updates Outlook on Medical Device and Equipment Stocks 2
(Date:7/29/2015)... , July 29, 2015  PDL BioPharma, Inc. (NASDAQ: ... into a revenue interest assignment agreement (the "Agreement") in ... (NASDAQ: ARIA ) with up to $200 million ... the net revenues of Iclusig ® (ponatinib).  Funding ... two tranches of $50 million each, with the initial ...
(Date:7/29/2015)... , July 29, 2015 Cogentix Medical, Inc. (NASDAQ: ... the urology market, will release financial results for the first ... after the market close on Monday, August 10, 2015. ... webcast to discuss these results on Monday, August 10, 2015 ... Rob Kill , President and Chief Executive Officer, and ...
(Date:7/29/2015)... 29, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... announced that it will release Second Quarter financial ... 2015. AcelRx management will host an investment-community conference ... Pacific Time) on Aug 3rd, 2015 to discuss ...
Breaking Medicine Technology:PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), a ... in respiratory critical care, will hold a conference call ... its March 6th announcement that SURFAXIN (lucinactant) has been ... Distress Syndrome (RDS) in premature infants at high risk ...
Cached Medicine Technology:Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant) 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: